Charles River Laboratories International, Inc. — Q3 2017 Form 10-Q
Business context and period. Unaudited results cover the three and nine months ended September 30, 2017; comparisons are to periods ended September 24, 2016. The company provides research models, discovery and safety assessment services, and manufacturing support to drug developers and other life-sciences customers.
Financial performance
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Revenue | $464.2 million | $425.7 million | $1,379.1 million | $1,214.6 million |
| Operating income | $74.0 million | $58.8 million | $224.8 million | $168.3 million |
| Operating margin | 15.9% | 13.8% | 16.3% | 13.9% |
| Net income attributable to common shareholders | $52.5 million | $37.7 million | $153.2 million | $110.1 million |
| Diluted EPS | $1.08 | $0.79 | $3.16 | $2.30 |
| Operating cash flow | — | — | $193.8 million | $198.3 million |
Q3 revenue rose 9.0%; service revenue increased 11.6% and product revenue 3.5%. Nine-month revenue rose 13.5%, led by service revenue growth of 19.1%. DSA was the largest growth contributor: revenue increased 14.4% in Q3 and 22.2% year to date. Manufacturing revenue grew 7.1% and 11.5%, respectively; RMS increased 0.9% and 1.0%. Foreign exchange added 1.0% to Q3 revenue but reduced nine-month revenue by 1.0%.
Management attributed higher operating income and margins to increased DSA demand, acquisitions, and productivity initiatives. Nine-month cash from operations was slightly lower despite higher earnings, principally due to working-capital timing, lower deferred revenue, and the divestiture gain. Capital expenditures were $53.9 million year to date, versus $29.6 million; investing cash outflow was $39.8 million, versus $617.7 million, reflecting the prior-year WIL Research acquisition and 2017 CDMO sale proceeds.
Liquidity, debt, and capital allocation
- At September 30, 2017, cash and equivalents were $123.6 million and investments were $30.4 million. Total current assets were $782.4 million and current liabilities $415.8 million.
- Total debt was $1.158 billion, down from $1.213 billion at December 31, 2016; the balance sheet also reported $30.9 million of capital lease obligations. The weighted-average debt interest rate was 2.26%. Debt was primarily floating-rate.
- The company reported compliance with credit-facility covenants. A 100-basis-point rate increase was estimated to add $11.5 million to annual pretax interest expense.
- Nine-month financing cash outflow was $155.5 million, including $106.9 million of treasury-stock purchases and net debt and lease payments. The company repurchased 1.0 million shares for $90.6 million under its program; $129.1 million remained authorized at quarter-end.
- Management stated existing funds, operating cash generation, and access to financing were sufficient for the foreseeable future.
Material changes, outlook, and risks
- Q3 net income included stronger venture-capital investment gains; nine-month results also included a $10.6 million gain on the February 2017 CDMO divestiture. The sale generated $72.5 million of proceeds, net of transferred cash and working-capital adjustments. The gain and investment returns are notable non-recurring or variable contributors; the divestiture also increased the nine-month effective tax rate to 32.2%, from 30.4%.
- In August, the company acquired Brains On-Line for $21.3 million cash, with contingent payments of up to approximately $7.9 million based on performance. It expands CNS discovery capabilities and is included in DSA.
- On November 8, 2017, after quarter-end, the company committed to close its Maryland RMS production facility before the end of 2018. Expected costs are $18–$24 million through fiscal 2018, mostly non-cash; cash costs are not expected to exceed $6 million.
- No quantified revenue or earnings guidance is provided in the supplied filing text. The company cautions that results are subject to business, market, foreign-exchange, interest-rate, acquisition, and other risks; it reported no material changes to the risk factors in its 2016 Form 10-K.
- Adoption of the new revenue-recognition standard was planned for 2018 using the modified retrospective method. Management preliminarily expected certain Biologics study revenue to shift from recognition over time to recognition at a point in time.
- Litigation matters were described as ordinary-course matters not expected to have a material adverse effect. The company had $25.2 million of unrecognized tax benefits and ongoing tax controversies; it did not expect their resolution to materially affect results or financial position.
Important facts for investors to verify
- How much of DSA growth and margin improvement reflects durable underlying demand and productivity versus acquisitions and currency.
- The sustainability of operating cash generation given higher receivables and working-capital outflows, and planned capital investment.
- Floating-rate debt exposure, leverage covenant headroom, and the effect of interest-rate changes.
- The final costs, timing, and operating impact of the Maryland facility closure, along with execution of the CDMO divestiture and Brains On-Line integration.
- The effect of revenue-recognition changes on Biologics and other businesses, and the recurrence of venture-capital gains and other income items.